Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 3:9:21-24.
doi: 10.1016/j.jbo.2017.09.003. eCollection 2017 Nov.

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials

Zhicai Zhang  1 , Feifei Pu  2 , Zengwu Shao  1
Affiliations

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials

Zhicai Zhang et al. J Bone Oncol. .

Abstract

Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases.

Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles. The fixed-effects model and random-effects model were used to summarize relative estimates and 95% confidence intervals (CIs) according to the heterogeneity of the included studies.

Results: Three randomized controlled trials (RCTs) including 4050 patients were identified in this meta-analysis study. The pooled analysis showed that denosumab could significantly reduce SREs, series SREs [Odds Ratio (OR) = 0.84; 95% CI, 0.74-0.95, I2 = 0%, P = 0.008] in patients with bone metastases as compared with ZA. Similar results of spinal cord compression SRE and surgery to bone SRE were obtained with (OR = 0.84; 95% CI, 0.70-1.01, I2 = 0%, P = 0.07) and (OR = 0.92; 95% CI, 0.78-1.08, I2 = 0%, P = 0.28) separately, radiation to bone SRE (OR = 0.72; 95% CI, 0.46-1.10, I2 = 11%, P = 0.13) and pathological fracture SRE (OR = 0.78; 95% CI, 0.35-1.73, I2 = 25%, P = 0.54) showed similar results, there were no significant difference between denosumab and ZA in patients with bone metastases.

Conclusion: Denosumab was more effective than ZA in reducing the incidence of SRE in patients with bone metastases.

Keywords: Bone metastases; Denosumab; Meta- analysis; Skeletal-related event; Zoledronic acid.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of the literature search.
Fig. 2
Fig. 2
Forest plot: summary OR of denosumab compared with ZA for series SREs.
Fig. 3
Fig. 3
Forest plot: summary OR of denosumab compared with ZA for radiation to bone SRE.
Fig. 4
Fig. 4
Forest plot: summary OR of denosumab compared with ZA for pathological fracture.
Fig. 5
Fig. 5
Forest plot: summary OR of denosumab compared with ZA for spinal cord compression.
Fig. 6
Fig. 6
Forest plot: summary OR of denosumab compared with ZA for surgery to bone SRE.
See this image and copyright information in PMC

References

    1. Coleman R.E. Skeletal complications of malignancy. Cancer. 1997;80:1588–1594. - PubMed
    1. Berenson J.R., Lichtenstein A., Porter L. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 1998;16:593–602. - PubMed
    1. Saad F., Gleason D.M., Murray R. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002;94:1458–1468. - PubMed
    1. Johnson J.R., Williams G., Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 2003;21:1404–1411. - PubMed
    1. Major P.P., Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am. J. Clin. Oncol. 2002;25:S10–S18. - PubMed

LinkOut - more resources